NASDAQ:SNTI Senti Biosciences Q3 2026 Earnings Date & Estimates $0.19 +0.01 (+6.62%) Closing price 10/27/2026 04:00 PM EasternExtended Trading$0.19 0.00 (-0.37%) As of 08:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Senti Biosciences is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Senti Biosciences in Q3 2026Senti Biosciences is expected to post earnings of -$0.21 per share on revenue of $16 thousand. In the same quarter a year earlier Senti Biosciences reported -$0.69 per share. Senti Biosciences last reported on August 14, 2026, posting -$0.41 per share and missing the -$0.33 consensus estimate. Senti Biosciences has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.21Expected Revenue$16 thousandPrior-Year EPS-$0.69Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.41 (Missed by -$0.08)Last Quarter Revenue$17 thousandEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Senti Biosciences Q3 2026 Earnings FAQ When does Senti Biosciences report Q3 2026 earnings? Senti Biosciences (NASDAQ:SNTI) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Senti Biosciences' Q3 2026 earnings call? Senti Biosciences' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Senti Biosciences? Analysts expect Senti Biosciences to post earnings of -$0.21 per share for Q3 2026. How much revenue is Senti Biosciences expected to report? The consensus revenue estimate for Senti Biosciences is $16 thousand for Q3 2026. Senti Biosciences Earnings HeadlinesSNTI - Senti Biosciences Holdings, Inc.October 24, 2026 | seekingalpha.comSenti Biosciences Holdings IncAugust 11, 2026 | cnn.comAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buying now averaging $7-9 billion per month. Bank of America, JPMorgan, and Wells Fargo have all raised their 2026 gold price targets to $6,000-$6,300 per ounce, citing accelerating demand. Cedar Gold Group's free Wealth Protection Playbook explains how eligible 401(k), IRA, or TSP holders can move funds into physical gold tax-deferred.October 28 at 1:00 AM | Cedar Gold Group (Ad)Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...July 15, 2026 | markets.businessinsider.comSenti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology PlatformJuly 15, 2026 | globenewswire.comSenti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note StructureMay 16, 2026 | tipranks.comSee More Senti Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email. Email Address About Senti BiosciencesSenti Biosciences (NASDAQ:SNTI) is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue. Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs. Its pipeline has included logic-gated therapies designed to integrate multiple antigen signals, with investigational programs targeting cancers such as acute myeloid leukemia and colorectal cancer. These products remain subject to clinical development and regulatory review. Founded in 2016, the company is headquartered in South San Francisco, California, and primarily conducts its research and development activities in the United States. Senti Biosciences was founded by scientists and entrepreneurs in the fields of synthetic biology and cell therapy, including Dr. Tim Lu, who has served as a senior company leader and co-founder.View Senti Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Taiwan Semiconductor Flexes Pricing Power on AI's FrontlineHidden in Plain Sight: 2 Earnings Winners Investors May Have MissedApple's Foldable iPhone Sold Out in Minutes, But Wall Street Has QuestionsCoca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest StrengthWhirlpool's Stock Collapse Raises a Bigger Question About Its Recovery PotentialAnalysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the Stock Upcoming Earnings Starbucks (10/29/2026)Amazon.com (10/29/2026)Anheuser-Busch InBev SA/NV (10/29/2026)Mondelez International (10/29/2026)Altria Group (10/29/2026)Cheniere Energy (10/29/2026)TotalEnergies (10/29/2026)Arthur J. Gallagher & Co. (10/29/2026)Lloyds Banking Group (10/29/2026)Bristol Myers Squibb (10/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
